ClinicalTrials.gg
RecruitingNCT07692269MIED-RCTUpdated Sep 8, 2026

Mindfulness Intervention for Emotional Distress: An EEG Study

An interventional study of MIED and PMR in Emotional Distress, Anxiety and Depression, sponsored by Peking University. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Peking University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Depression by Peking University — 10 open to participants now, 13 under way, none of them phase 3. Depression · Peking University.

Planned enrollment
14th of 20
160 · median 200
Started
2026
with 3 others
No phase
19 of 21
10 open now
Primary completion
2026-12
later than 8 of 12 live
Registered
19th of 21
by date

Among the 21 studies in Depression by Peking University, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2026, is one of 19 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 19th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

10 of the 21 studies in Depression by Peking University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Depression by Peking University, or all of them as a file.
02

Study summary

This is a randomized controlled trial examining the efficacy and neural mechanisms of a standardized Mindfulness Intervention for Emotional Distress (MIED) in adults with subclinical emotional distress. One hundred and sixty participants will be randomly assigned to either an 8-week MIED program or an 8-week Progressive Muscle Relaxation (PMR) active control. The primary aim is to evaluate whether MIED reduces anxiety symptoms and reshapes multilevel emotional processing as measured by multimodal EEG (resting-state FAA/theta, Fast Periodic Visual Stimulation, and event-related potentials). Assessments occur at baseline (T1), post-intervention (T2), and 1-month follow-up.

Read the detailed description

Background. Emotional distress is a subclinical mental health condition characterized by persistent anxiety, depression, stress, and emotion dysregulation. Mindfulness interventions have shown efficacy across transdiagnostic emotional disorders, yet their neurocognitive mechanisms remain incompletely understood.

Objective. This study aims to (1) verify the dynamic intervention effects of MIED on emotional distress; (2) reveal neuroplastic changes across multiple levels of emotional processing; (3) explore associations between neural changes and symptom improvement; and (4) examine whether strategy acquisition is linked to neural remodeling.

Design. This is a two-arm, parallel-group, randomized controlled trial with single (outcomes assessor) blinding. Participants (N = 160) aged 18-50 with elevated psychological distress (K10 > 21) will be randomized (1:1; block sizes 4 and 6) to:

Experimental arm: MIED - 8 weeks of weekly 2.5-hour group sessions plus daily 15-minute app-based(IMIED) home practice.

Active comparator arm: PMR - 8 weeks of structurally matched weekly 2.5-hour group sessions plus daily 15-minute audio home practice.

Assessments. Baseline (T1), post-intervention (T2, within 2 weeks after Week 8), and 1-month follow-up (online). During the intervention, brief online tracking (GAD-7, PHQ-9) occurs at Weeks 2, 4, and 6.

Neuroimaging. Multimodal EEG includes: (a) 5-minute resting-state EEG (FAA, theta power); (b) Fast Periodic Visual Stimulation (FPVS; 6 Hz base frequency, 1.2 Hz oddball for emotional faces) to index automatic emotional processing; (c) Task-based ERP ( LPP at 400-800 ms ) during emotional picture rating to index controlled emotional processing.

Primary Mechanistic Outcome. LPP early-window (400-800 ms) mean amplitude under negative stimulus conditions.

Statistical Analysis. Primary efficacy analyses will use linear mixed-effects models (LMM) under the intention-to-treat (ITT) principle. Missing data will be handled by restricted maximum likelihood (REML) assuming MAR, with multiple imputation as a sensitivity analysis. Hierarchical multiple comparison control: primary outcome (GAD-7) at α = 0.05 (two-sided); key secondary outcome (PHQ-9) reported with nominal and corrected p-values; remaining psychological and EEG measures corrected by Benjamini-Hochberg FDR.

03

Conditions studied

  • Emotional Distress
  • Anxiety
  • Depression
  • Stress (Psychology)
  • Psychological

Browse trials for

04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 160 is above the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Peking University is the lead sponsor of 420 studies on the registry; 124 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-50 years Kessler Psychological Distress Scale (K10) score > 21 No systematic mindfulness or progressive muscle relaxation practice in the past 6 months (frequency \< 1 time per week) Normal or corrected-to-normal vision Voluntary participation with signed

Exclusion criteria

Exclusion Criteria:

  • Prior diagnosis of schizophrenia, bipolar disorder, or other severe mental disorders by a psychiatrist Suicidal plan, self-injury, or need for emergency psychological crisis intervention in the past month Currently receiving systematic psychotherapy or participating in other psychological intervention programs Started psychiatric medication within the past 3 months or on an unstable medication dosage History of epilepsy, severe brain injury, or other neurological disorders that may affect EEG measurement Severe vision or hearing impairment or other conditions preventing completion of study procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    PMR (Progressive Muscle Relaxation)

    A structured 8-week Progressive Muscle Relaxation program matched to MIED in frequency, duration, and format: weekly 2.5-hour group sessions plus daily 15-minute audio home practice. Participants progress from tension-release of major muscle groups to full-body relaxation.

    Behavioral: PMR

  • Experimental
    MIED (Mindfulness Intervention for Emotional Distress)

    A standardized 8-week transdiagnostic mindfulness program: weekly 2.5-hour group sessions plus daily 15-minute app-based home practice (iMIED). Content includes mindful breathing, body scan, mindful walking, and loving-kindness meditation.

    Behavioral: MIED

Interventions

  • BehavioralMIED

    A standardized 8-week transdiagnostic mindfulness intervention (MIED) based on the Unified Protocol and contemporary mindfulness theory. Participants attend weekly 2.5-hour group sessions and complete daily 15-minute home practice via a mobile app (iMIED). Core practices include mindful breathing, body scan, mindful walking, and loving-kindness meditation. The program emphasizes four key strategies: engagement with life, distress tolerance, cognitive flexibility, and emotion-driven behavioral regulation. All sessions follow a structured manual to ensure fidelity.

  • BehavioralPMR

    A structured 8-week Progressive Muscle Relaxation program matched to MIED in frequency, duration, and format. Participants attend weekly 2.5-hour group sessions and complete daily 15-minute audio-guided home practice. The program progresses from systematic tension-release of major muscle groups to full-body relaxation, controlling for non-specific therapeutic factors (group support, time, expectancy). All sessions are manualized to ensure consistent delivery.

07

What researchers measure

Primary outcomes

  1. Generalized Anxiety Disorder-7(GAD-7)

    The GAD-7 is a 7-item self-report measure of anxiety symptom severity over the past 2 weeks. Total scores range from 0 to 21. The primary analysis examines the Group × Time interaction using linear mixed-effects models across all six assessment points (Weeks 0, 2, 4, 6, 8, and 12).

    Time frame: Baseline (T1, Week 0), Week 2, Week 4, Week 6, post-intervention (T2, Week 8), and 1-month follow-up (Week 12)

Secondary outcomes

  1. Patient Health Questionnaire(PHQ-9)

    The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report measure assessing the severity of depressive symptoms over the past two weeks. Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms (worse outcome).

    Time frame: Baseline (T1, Week 0), Week 2, Week 4, Week 6, post-intervention (T2, Week 8), and 1-month follow-up (Week 12)

  2. Five Facet Mindfulness Questionnaire-20 (FFMQ-20)

    The Five Facet Mindfulness Questionnaire-20 (FFMQ-20) is a 20-item self-report measure assessing trait mindfulness across five facets. Total scores range from 20 to 100, with higher scores indicating greater mindfulness (better outcome).

    Time frame: Baseline (T1,week 0) and post-intervention (T2, Week 8)

  3. Distress Tolerance Scale (DTS)

    The Distress Tolerance Scale (DTS) is a 15-item self-report measure assessing an individual's perceived ability to tolerate and manage emotional distress. Total scores range from 15 to 75, with higher scores indicating greater distress tolerance (better outcome).

    Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)

  4. Cognitive Flexibility Inventory (CFI)

    The Cognitive Flexibility Inventory (CFI) is a 20-item self-report measure assessing cognitive flexibility. Total scores range from 20 to 140, with higher scores indicating greater cognitive flexibility (better outcome).

    Time frame: Baseline (T1,week0) and post-intervention (T2,week8)

  5. Excessive Emotional Behavior Scale (EEBS)

    EEBS is a self-report measure assessing the tendency to engage in excessive emotional behaviors in response to emotional distress. Higher scores indicate greater levels of excessive emotional behavior.

    Time frame: Baseline (T1,week 0) and post-intervention (T2,week8)

  6. Engagement with Life Scale (ELS)

    ELS is a self-report measure assessing the extent to which individuals engage in meaningful and valued life activities despite experiencing emotional distress. Higher scores indicate greater engagement with life.

    Time frame: Baseline (T1,week0) and post-intervention (T2,week8)

  7. Chinese Perceived Stress Scale (CPSS)

    The Chinese Perceived Stress Scale-14 (CPSS-14) is a 14-item self-report measure assessing perceived stress during the past month. Total scores range from 0 to 56, with higher scores indicating greater perceived stress (worse outcome).

    Time frame: baseline(T1,week 0),post-intervention(T2,week8)

  8. Late Positive Potential (LPP) early window (400-800 ms)

    Late Positive Potential (LPP; 400-800 ms mean amplitude) is an ERP component reflecting sustained controlled processing of emotional stimuli. Mean LPP amplitude within the 400-800 ms time window will be quantified at CPz, Cz, P3, Pz, and P4 during a 20-minute emotional picture rating task. Based on the best available evidence and theoretical rationale from previous mindfulness and emotion regulation studies, LPP was selected as a candidate mechanistic outcome.

    Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)

  9. Frontal Alpha Asymmetry (FAA)

    Frontal Alpha Asymmetry (FAA; 8-13 Hz log-transformed alpha power difference) is a resting-state EEG measure of frontal hemispheric asymmetry, associated with affective processing, emotion regulation, and approach-withdrawal motivational tendencies. FAA will be calculated as the log-transformed alpha power difference between homologous frontal electrode pairs during a 5-minute resting-state EEG recording. The primary specification is FAAln = ln(F4) - ln(F3), using absolute alpha power at F3/F4. As an exploratory specification, FAAlnrel = ln\[rel(F4)\] - ln\[rel(F3)\] will also be examined, where rel denotes alpha power divided by total (1-45 Hz) power at the same electrode. This addition does not alter the primary specification and was made prior to any analysis of post-intervention EEG data and prior to unblinding of group allocation.

    Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)

  10. Frontal theta power

    Frontal theta power (4-8 Hz) is a resting-state EEG measure associated with cognitive control, attentional regulation, and emotion regulation. Absolute or relative theta power within the 4-8 Hz frequency band will be quantified from frontal electrodes (e.g., Fz, F3, and F4) during a 5-minute resting-state EEG recording. Based on the best available evidence and theoretical rationale from previous mindfulness and cognitive control studies, frontal theta power was selected as a candidate mechanistic outcome.

    Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)

  11. Fast Periodic Visual Stimulation Signal-to-Noise Ratio (FPVS-SNR)

    Fast Periodic Visual Stimulation Signal-to-Noise Ratio (FPVS-SNR) is an EEG-derived measure quantifying neural responses to periodically presented emotional visual stimuli. Change in FPVS-SNR from baseline to post-intervention will be assessed during the emotional fast periodic visual stimulation task.Based on the best available evidence and theoretical rationale, FPVS-SNR was selected as a candidate mechanistic outcome to assess changes in visual emotional processing following the intervention.

    Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)

  12. Kessler Psychological Distress Scale (K10)

    The Kessler Psychological Distress Scale (K10) is a 10-item self-report measure assessing non-specific psychological distress during the past four weeks. Total scores range from 10 to 50, with higher scores indicating greater psychological distress (worse outcome).

    Time frame: Baseline (T1,week 0) and post-intervention (T2, Week 8)]

Other outcomes

  1. Meditation-Related Adverse Events Scale (MRAES-MBP)

    The MRAES-MBP is a self-report measure assessing meditation-related adverse events experienced during participation in mindfulness-based programs, including their occurrence and severity.

    Time frame: Week 2, Week 4, Week 6, and Week 8

  2. Simplified adverse events questionnaire

    A simplified safety monitoring questionnaire administered biweekly to the PMR group to assess somatic discomfort and emotional reactions related to muscle relaxation practice.

    Time frame: Week 2, Week 4, Week 6, and Week 8

  3. Credibility/Expectancy Questionnaire (CEQ) score

    A 6-item measure of intervention credibility and improvement expectancy, administered to assess and control for non-specific expectancy effects as a covariate in primary efficacy analyses.

    Time frame: After the first group session (Week 1)

  4. Spectral Parameterization (FOOOF/specparam)-Derived Aperiodic and Periodic Parameters

    Spectral parameterization (FOOOF/specparam)-derived measures are exploratory resting-state EEG outcomes obtained by decomposing the neural power spectrum into periodic (oscillatory) and aperiodic (1/f-like) components (Donoghue et al., 2020). From 5-minute resting-state EEG recordings, the aperiodic exponent and offset will be estimated at midline electrodes Oz and Cz (2-40 Hz fit). Oscillatory alpha-peak parameters (center frequency, power, bandwidth) from the same parameterization will also be examined. Model-fit indices and peak-detection information will be used for quality control, not as intervention outcomes. Emerging evidence links aperiodic activity to arousal, affective processing, and meditation-related states; these measures are hypothesis-generating outcomes of intervention-related change. This exploratory analysis was added during a registration revision, prior to any analysis of post-intervention EEG data and prior to unblinding of group allocation.

    Time frame: Baseline (T1,week 0) and post-intervention (T2,week 8)

08

Study locations

1 of 1 sites recruiting
  • Peking University, School of Psychological and Cognitive Sciences
    Beijing, Beijing Municipality, China
    Recruiting
09

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be made publicly available because the study involves sensitive mental health data and participant privacy must be protected. Requests for additional information regarding the study may be directed to the corresponding author.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 9, 2026
StartActual
Jul 4, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07692269
Lead sponsor
Peking University
Responsible party
Xinghua Liu (Director, Peking University) — Principal investigator
First posted
Jul 9, 2026
Start date
Jul 4, 2026
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Qinsi Zheng
Contact
qszheng25@stu.pku.edu.cn
+86 13457651658
Xinghua Liu
Contact
xinghua_liu@pku.edu.cn
+86 13371669818
Xinghua Liu, Dr.
principal investigator · School of Psychological and Cognitive Science,Peking University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion